Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1200mg Cannabidiol by capsules twice daily[1] Cannabidiol[1] D10915 [2] CNR1,
CNR2 💬		[4] Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬[1] 46
2400mg Cannabidiol by capsules twice daily[1] Cannabidiol[1] D10915 [2] CNR1,
CNR2 💬		[4] Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬[1] 46
3Abacavir 300mg twice daily[1] Abacavir[2] D00891 ,
D07057 		--[1] 265
4ACTHAR Gel 40 units twice weekly[1] Corticotropin[1] D00146 [1] MC2R 💬[5] Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬[1] 84
5ACTHAR Gel 80 units twice weekly.[1] Corticotropin[1] D00146 [1] MC2R 💬[5] Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬[1] 84
6All subjects will receive maraviroc 300mg orally twice a day for 6 weeks[1] Maraviroc[1] D06670 [1] CCR5 💬[9] Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Toxoplasmosis, Viral carcinogenesis, Viral protein interaction with cytokine and cytokine receptor 💬[1] 84
7AZLI 75 mg two times a day (BID)/ three times a day (TID)----[1] 299
8AZLI 75 mg two times a day (BID)/three times a day (TID)----[1] 299
9Budesonide 0.5mg orodispersible tablet twice daily[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
10Budesonide 1mg orodispersible tablet twice daily[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
11Burosumab
(Synonym: Burosumab-twza)		[1] Burosumab (Synonym: burosumab-twza)[1] D10913 (Name: Burosumab-twza)[1] FGF23 💬[11] Breast cancer, Calcium signaling pathway, Gastric cancer, MAPK signaling pathway, Melanoma, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton 💬[1] 238
12Chinese herbal concoction twice a day for 6 months----[1] 60
13Colistimethate 75 mg inhaled two times daily[1] Colistimethate[1] D02049 --[1] 299
14Combination Product: Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator[3] Acetate,
Hydrocortisone,
Hydrocortisone acetate		[2] D00088 ,
D00165 		[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 97
15Crysvita (burosumab-twza) Treatment[1] Burosumab (Synonym: burosumab-twza)[1] D10913 (Name: Burosumab-twza)[1] FGF23 💬[11] Breast cancer, Calcium signaling pathway, Gastric cancer, MAPK signaling pathway, Melanoma, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton 💬[1] 238
16ETD001 multiple twice daily doses----[1] 299
17Fampridine-SR b.i.d. (Twice Daily)[1] Dalfampridine[1] D04127 [4] KCNA4,
KCNC3,
KCND2,
KCND3 💬		[4] Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬[1] 13
18Fluticasone Propionate, 800 mcg twice daily (post 4FED failure)[1] Fluticasone propionate[1] D01708 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
19Fluticasone Propionate, 880 mcg twice daily (after 6FED failure)[1] Fluticasone propionate[1] D01708 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
20Gentamicin infusions twice a week for six months[1] Gentamicin[2] D01063 ,
D08013 		--[1] 113
21High dose BIBF 1120 twice daily----[1] 85
22Intermediate dose BIBF 1120 twice daily----[1] 85
23JNJ-54781532 75 mg twice daily----[1] 97
24Low dose BIBF 1120 twice daily----[1] 85
25Mesalamine Twice-Daily[1] Mesalazine[1] D00377 --[1] 97
26Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH)[1] Tripterygium wilfordii whole---[1] 66
27Mycophenolate mofetil orally 1000 mg twice a day (BID)[2] Mycophenolate mofetil,
Mycophenolic acid		[4] D00752 ,
D05094 ,
D05095 ,
D05096 		[2] IMPDH1,
IMPDH2 💬		[3] Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬[1] 222
28Order of two elements of surgical procedure----[1] 51
29Other: Dummy Tripterygium wilfordii Hook F (TwHF)[1] Tripterygium wilfordii whole---[1] 46
30Part 1 Levulan surface application twice----[1] 34
31Part 1 Levulan surface application twice with microneedling----[1] 34
32PXT3003 Dose 2 (equivalent to twice Dose 1)----[1] 10
33Radiation: PET/CT Scan: Two PET scans using 1. C-11 HED and 2. N-13 Ammonia or rubidium-82[2] Ammonia,
Rubidium		[1] D02916 --[1] 86
34TOBI™ Podhaler™ 112 mg inhaled twice daily----[1] 299
35Tofacitinib 5 mg twice daily[1] Tofacitinib[1] D09970 [4] JAK1,
JAK2,
JAK3,
TYK2 💬		[37] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬[1] 84
36Treatment of MTX and TwHF----[1] 46
37Treatment of TwHF----[1] 46
38Tripterygium wilfordii (TW)[1] Tripterygium wilfordii whole---[2] 66, 222
39Tripterygium wilfordii Hook F (TwHF)[1] Tripterygium wilfordii whole---[1] 46
40TW----[1] 222
41TwHF----[1] 46
42Twice-daily dosage with 0.5% cyclosporine-A eyedrops[1] Cyclosporine[1] D00184 [5] PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬		[33] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬[1] 90